Literature DB >> 8198572

Differential expression of members of the N-formylpeptide receptor gene cluster in human phagocytes.

M Durstin1, J L Gao, H L Tiffany, D McDermott, P M Murphy.   

Abstract

The human genes for two N-formylpeptide phagocyte chemoattractant receptors (gene symbols FPR1 and FPRL1) cross-hybridize with each other and with FPRL2, a human gene of unknown expression and function. The FPR1 product is approximately 1000-fold more sensitive than the FPRL1 product to N-formylpeptides. We now report cloning of the first cDNA for FPRL2 and the first description of the RNA distribution in normal human phagocytes for all three genes. FPR1 and FPRL1 are expressed in neutrophils and monocytes. In contrast, FPRL2 RNA is detectable in monocytes but not in neutrophils, and its product could not be activated by N-formylpeptides. Thus, the regulation of FPRL2 gene expression in vivo differs from FPR1 and FPRL1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198572     DOI: 10.1006/bbrc.1994.1685

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Expression and signaling of formyl-peptide receptors in the brain.

Authors:  Fabio Cattaneo; Germano Guerra; Rosario Ammendola
Journal:  Neurochem Res       Date:  2010-11-02       Impact factor: 3.996

Review 2.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

3.  CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor.

Authors:  Amanda Welin; Halla Björnsdottir; Malene Winther; Karin Christenson; Tudor Oprea; Anna Karlsson; Huamei Forsman; Claes Dahlgren; Johan Bylund
Journal:  Infect Immun       Date:  2014-10-20       Impact factor: 3.441

4.  A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis.

Authors:  J Bylund; T Christophe; T Cristophe; F Boulay; A Romero; K Hellstrand; C Dahlgren
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

5.  A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Authors:  Aram Elagoz; Duncan Henderson; Poda Suresh Babu; Sylvia Salter; Caroline Grahames; Lorna Bowers; Marie-Odile Roy; Patricia Laplante; Eric Grazzini; Sultan Ahmad; Paola M C Lembo
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

6.  Molecular evolution of the N-formyl peptide and C5a receptors in non-human primates.

Authors:  V Alvarez; E Coto; F Setién; S González-Roces; C López-Larrea
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 7.  Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Ye Zhou; Yingying Le; Xiuwu Bian; Ji Ming Wang
Journal:  Cancer Lett       Date:  2008-04-22       Impact factor: 8.679

8.  Prolonged elevation of intracellular cyclic AMP levels in U937 cells increases the number of receptors for and the responses to formylmethionyl-leucylphenylalanine, independently of the differentiation process.

Authors:  T Fischer; R Zumbihl; J Armand; P Casellas; B Rouot
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

9.  Mitochondrial N-formyl methionine peptides associate with disease activity as well as contribute to neutrophil activation in patients with rheumatoid arthritis.

Authors:  Bhargavi Duvvuri; Al Anoud Baddour; Kevin D Deane; Marie L Feser; J Lee Nelson; M Kristen Demoruelle; Christian Lood
Journal:  J Autoimmun       Date:  2021-03-10       Impact factor: 7.094

10.  Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus.

Authors:  J C Boer; U M Domanska; H Timmer-Bosscha; I G J Boer; C J C de Haas; J V Joseph; F A E Kruyt; E G E de Vries; W F A den Dunnen; J A G van Strijp; A M E Walenkamp
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.